Lumos Diagnostics posts $6.12M H1 sales, lands $317M US FebriDx deal
Lumos Diagnostics reported 1H FY26 revenue of $6.12 million, with FebriDx sales rising to $1.68 million and a net loss widening to $4.88 million despite a $0.76 million cash inflow. The company secured a six-year, $317 million US distribution agreement for FebriDx and awaits FDA CLIA waiver by March 31.
1. 1H FY26 Financial Results
Lumos Diagnostics recorded revenue of $6.12 million for the six months ended December 31, 2025, down from $6.31 million a year earlier. Product sales, led by FebriDx, jumped to $1.68 million from $0.84 million, while services income fell to $4.44 million from $5.47 million; gross profit held steady at $4.15 million with a 68% margin.
2. Profitability and Cash Flow
Operating expenses increased to $8.0 million, driving an adjusted EBITDA loss of $1.38 million versus $0.94 million prior year and a net loss after tax of $4.88 million compared with $2.80 million. Net operating cash inflow was $0.76 million, a $7.08 million improvement, supported by higher customer receipts and $2.75 million in government grant cash.
3. US Distribution and Regulatory Milestones
The company signed a six-year exclusive US distribution agreement with PHASE Scientific for FebriDx valued at $317 million, receiving $3.5 million to date and expecting a $5.0 million prepaid commitment upon FDA CLIA waiver. FebriDx has been submitted for CLIA waiver clearance by March 31, 2026, has Medicare reimbursement in seven jurisdictions, and has launched a BARDA-funded pediatric study with $1.9 million in milestone receipts.